Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Modena
- Target Recruit Count
- 2500
- Registration Number
- NCT00629278
- Locations
- 🇮🇹
Ospedal San Andrea, Vercelli, Italy
🇮🇹Ospedale Civile di Ivrea, Ivrea, Italy
🇮🇹Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino, Turin, Italy
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
- Conditions
- Cervical CancerUterine Cancer
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2014-07-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00626561
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00622466
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- EsophagealToxicity
- Interventions
- Genetic: Manganese Superoxide Dismutase Plasmid LiposomeDrug: carboplatinDrug: paclitaxelRadiation: Radiation Therapy
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Joel Greenberger
- Target Recruit Count
- 18
- Registration Number
- NCT00618917
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00618826
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: PaclitaxelDrug: All -trans Retinoic Acid (ATRA)
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 69
- Registration Number
- NCT00617409
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 150
- Registration Number
- NCT00616031
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Loma Linda University
- Target Recruit Count
- 28
- Registration Number
- NCT00614484
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
- Conditions
- Ovarian NeoplasmsOvarian Cancer
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 211
- Registration Number
- NCT00610714
- Locations
- 🇬🇧
Research Site, Coventry, United Kingdom
Pharmacokinetics Study of Liposomal Paclitaxel in Humans
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Shandong Luye Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT00606515
- Locations
- 🇨🇳
Cancer Hospital of Fudan University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.